Erratum: Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.

The authors would like to make a correction to the data presented in this article published in the April 2021 issue of the AnnalsATS (1). On February 11, 2022, the authors were made aware of a central coding error in the dataset for the Pulmonary Hypertension Association Registry (PHAR), which impacted the calculation of the summary scores of the health-related quality of life instruments the Short Form 12-Physical Component Score (SF12-PCS) and the Short Form 12-Mental Component Score (SF12-MCS). This error at the PHAR coordinating center led to the reverse coding of four of the twelve items in the Short Form 12 health-related quality of life instrument, and as a result, the results of any analysis performed on the dataset which reported SF12-PCS or SF12-MCS.

Repeating the initial analysis with the corrected dataset did lead to some changes, which are reported below.

Results

Health-related Quality of Life

The baseline SF12-MCS scores should be changed to 40.7 ± 12.6 for participants with methamphetamine-associated pulmonary arterial hypertension (Meth-APAH) and to 47.8 ± 11.4 for participants with idiopathic pulmonary arterial hypertension (PAH).

The baseline SF12-PCS scores should be changed to 34.9 ± 10.5 for participants with Meth-APAH and to 35.3 ± 11.0 for participants with idiopathic PAH.

The text in the paragraph should be revised to state that there was no association between Meth-APAH and SF12-PCS.

The text in the paragraph should be revised to highlight that the association between Meth-APAH and impaired generic-mental health-related quality of life was greater than the minimally clinically important difference.

Discussion

The first paragraph of the discussion should have the words “and generic-mental” to sentence 3 after “PAH-specific.”

The last sentence of paragraph 4 of the discussion should be deleted.

Table 4

The unadjusted association between Meth-APAH and SF12-PCS should be changed to an effect estimate of −0.6; 95% confidence interval (CI), −2.5 to 1.3; P = 0.550. The adjusted association should be changed to an effect estimate of −1.8, 95% CI: −3.9 to 0.37, P = 0.106.

The unadjusted association between Meth-APAH and SF12-MCS should be changed to an effect estimate of −6.8; 95% CI, −9.1 to −4.4; P < 0.001. The adjusted association should be changed to an effect estimate of −5.7; 95% CI, −8.2 to −3.2; P < 0.001.

Table E4

In sensitivity analysis 1 the association between Meth-APAH and SF12-PCS should appear as an effect estimate of −0.7; 95% CI, −2.8 to 1.3; P = 0.476 and the association between Meth-APAH and SF12-MCS should appear as an effect estimate of −6.5; 95% CI, −8.9 to −4.1; P < 0.001.

In sensitivity analysis 2 the association between Meth-APAH and SF12-PCS should appear as an effect estimate of −1.0; 95% CI, −3.0 to 1.0; P = 0.305 and the association between Meth-APAH and SF12-MCS should appear as an effect estimate of −6.7; 95% CI, −8.9 to −4.4; P < 0.001.

In sensitivity analysis 3 the association between Meth-APAH and SF12-PCS should appear as an effect estimate of −1.7; 95% CI, −3.9 to 0.5; P = 0.121 and the association between Meth-APAH and SF12-MCS should appear as an effect estimate of −5.9; 95% CI, −8.4 to −3.4; P < 0.001.

In sensitivity analysis 4 the association between Meth-APAH and SF12-PCS should appear as an effect estimate of −1.5; 95% CI, −3.7 to 0.7; P = 0.180 and the association between Meth-APAH and SF12-MCS should appear as an effect estimate of −5.3; 95% CI: −7.9 to −2.8, P < 0.001.

In sensitivity analysis 5 the association between Meth-APAH and SF12-PCS should appear as an effect estimate of −1.6; 95% CI, −3.8 to 0.6; P = 0.144 and the association between Meth-APAH and SF12-MCS should appear as an effect estimate of −5.6; 95% CI, −8.1 to −3.1; P < 0.001.

Table E7

The original model for SF12-PCS should be changed to an effect estimate of −1.8; 95% CI, −3.9 to 0.37; P = 0.106, and the imputed model should be changed to an effect estimate of −1.7; 95% CI, −3.9 to 0.41; P = 0.114.

The original model for SF12-MCS should be changed to an effect estimate of −5.7; 95% CI, −8.2 to −3.2; P < 0.001, and the imputed model should be changed to an effect estimate of −5.6; 95% CI, −8.1 to −3.1; P < 0.001.

For the convenience of our readers, AnnalsATS is replacing the online version of the article with a corrected version.

Figure 2A and 2B (corrected).